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Abstract
Alterations in arachidonic acid metabolism are involved
in human carcinogenesis. Cyclooxygenase (COX) and
lipoxygenase (LOX) are key enzymes in this metabo-
lism. We analyzed the expression of 15S- lipoxygenase-2
(15-LOX-2) mRNA and protein in surgical specimens
from normal (N=37) and malignant (63) esophageal
tissues using in situ hybridization and immunohisto-
chemistry ( IHC), and in normal (1), premalignant (1),
and malignant (5) esophageal cell lines using Northern
and Western blotting. 15-LOX-2 was expressed in
normal esophageal epithelial cells (EECs) at the highest
levels, whereas an SV40-immortalized HET-1A line and
three of five esophageal cancer cell lines failed to
express it at detectable levels. 15-LOX-2 was detected in
76% (28/37) of the normal esophageal mucosae, but
only in 46% (29/63) of the cancer specimens using
IHC (P<.01). Transient transfection of 15-LOX-2 ex-
pression vectors into esophageal cancer cells signifi-
cantly inhibited the proliferation of 15-LOX-2–negative
cancer cells. The COX-2 inhibitor, NS398, induced 15-
LOX-2 expression in esophageal cancer cells, which is
associated with reduced cell viability. This study dem-
onstrated that 15-LOX-2 expression is lost in esoph-
ageal cancers and that the induction of 15-LOX-2 can
inhibit cancer cell proliferation. Further investigation of
the effects of nonsteroidal anti - inflammatory drugs on
15-LOX-2 expression and apoptosis in esophageal
cancer cells may be warranted.
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Introduction
Esophageal cancer is a significant worldwide health problem.
This disease typically is at an advanced pathologic stage at
diagnosis and is associated with a very poor prognosis,
reflected by an overall 5-year survival rate of less than 10%
[1,2]. Relatively less common in the United States than in
other countries, esophageal cancer annually accounts for an
estimated 13,100 new cases (only 1% of all diagnosed
cancers) and 12,600 deaths, and is the seventh leading
cause of death from cancer in American men [2]. Cancer
statistics [2 ] have shown that the incidence of esophageal
adenocarcinoma is increasing rapidly in the United States, for
reasons that are not clear. New approaches to the
prevention, early identification, and treatment of esophageal
cancer are urgently needed.
Epidemiologic and experimental studies have demonstrat-
ed beneficial effects of nonsteroidal anti - inflammatory drugs
(NSAIDs) in the prevention of human cancers, especially
those in the gastrointestinal tract [3–9]. For example, in
studies [4,5,9] of individuals who took NSAIDs regularly,
mortality from esophageal cancer was reduced by 40% to
50%. In addition, in animal models of esophageal carcino-
genesis, NSAIDswere shown to reduce the frequency and the
number of premalignant and malignant lesions [10,11]. More
recent data from our and others’ laboratories showed that
NSAIDs can induce tumor cells to undergo apoptosis [3–8,
12–15]. While inducing apoptosis, the cyclooxygenase-2
(COX-2) inhibitor, NS398, induced the release of cytochrome
C from the mitochondria, activating caspase-9 and caspase-3
and resulting in the cleavage of poly(ADP-ribose) polymerase
[8]. These NSAID effects were associated with the agents’
abilities to inhibit COX-2 enzymatic activity and to upregulate
the expression of 15S- lipoxygenase-1 (15-LOX-1) [14].
Another study [16], however, indicated that the modulation of
COX-2 and 15-LOX-1 may not explain all of the effects of
NSAIDs in cancer prevention and therapy.
The 15S - lipoxygenase-2 (15-LOX-2) enzyme is ex-
pressed in skin, cornea, lung, and prostate cells [17]. In
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contrast to its expression in differentiated secretory cells
in benign human prostate, 15-LOX-2 expression is reduced
in prostate adenocarcinomas [18,19], suggesting that the
alteration of this gene plays a role in carcinogenesis and that
the modulation of the gene’s expression could be a
mechanism for chemopreventive strategies. To better under-
stand the role of the 15-LOX-2 enzyme in carcinogenesis
and chemoprevention, we first examined the expression of
15-LOX-2 mRNA and protein in surgical specimens from
normal and malignant esophageal tissues using in situ
hybridization ( ISH) and immunohistochemistry ( IHC), and in
normal, premalignant, and cancerous esophageal cell lines
using Northern and Western blotting. We also investigated
the effects of 15-LOX-2 on cell proliferation using transient
transfection assay and, lastly, the effects of NS398 on
15-LOX-2 expression and cell viability in these cell lines.
Materials and Methods
Cell Lines and Surgical Specimens
The normal esophageal epithelial cells (EECs) were
derived from benign human esophageal mucosa and were
obtained from the Department of Surgery and Surgical Basic
Science, Graduate School of Medicine, Kyoto University
(Kyoto, Japan). The SV40- immortalized esophageal cell
line, HET-1A, was provided by Dr. Curtis Harris, Laboratory
of Human Carcinogenesis, National Cancer Institute
(Bethesda, MD) [20]. The esophageal cancer cell lines
TE-1, TE-3, TE-7, TE-8, and TE-12 were obtained from
the First Department of Pathology, Hiroshima University
School of Medicine (Hiroshima, Japan) [7].
Human esophageal tissue specimens were obtained from
the Department of Pathology, The University of Texas M.D.
Anderson Cancer Center (Houston, TX) and from InnoGe-
nex (San Ramon, CA). Sixteen samples came from
esophageal adenocarcinoma patients and 47 samples from
squamous cell carcinoma (SCC) patients (a total of 63 tumor
samples). There were 37 samples of morphologically normal
squamous esophageal mucosae from sectioned margins. Of
these 37, there were 33 paired tumor and normal samples.
All samples were routinely fixed in 10% buffered formalin,
embedded in paraffin, and cut into 4-m sections. One
section from each sample was stained with hematoxylin and
eosin for classification.
ISH
A previously described method of nonradioactive ISH was
used [21]. Briefly, a 15-LOX-2 cDNA fragment was cloned
from the prostate cancer cell line, PC3, using a primer set of
50 -TGCCTCTCGCCATCCAGCT-30 and 50 -TGTTCCCCTG
GGATTTAGATGGA- 30. The 1-kb polymerase chain reac-
tion (PCR) fragment was then subcloned into pTOPO 2.1
plasmid ( Invitrogen, Carlsbad, CA) and sequenced; it
exactly matched the previously reported 15-LOX-2 cDNA
sequence [17]. For ISH, the plasmid was linearized by
BamHI and labeled with digoxigenin-UTP by using T7
polymerase. The binding quality and the specificity of the
digoxigenin- labeled antisense riboprobe were verified using
negative control sections and compared with the results of
immunohistochemical studies.
Immunohistochemistry
The immunohistochemical localization of the 15-LOX-2
protein was performed using a modified avidin–biotin
complex (ABC) technique [18]. Tissue sections were
deparaffinized in xylene and rehydrated in a series of ethanol
solutions (100% to 50%). The endogenous peroxidase
activity was blocked by incubation in a 1% methanolic
hydrogen peroxide solution for 30 minutes. This procedure
was followed by preincubation with 20% normal goat serum
to minimize nonspecific binding of the second antibody. The
sections were then incubated at 238C for 4 hours with
polyclonal rabbit anti–15-LOX-2 antibody (see Ref. [18] ) at
a dilution of 1:800 in phosphate-buffered saline (PBS). After
being washed three times in PBS, the sections were
incubated with biotinylated with goat anti–rabbit IgG
(H+L) (Vector Laboratories, Burlingame, CA) for 30minutes
at 238C and then incubated with the ABC kit (Vector
Laboratories) for 30 minutes in darkness. They were then
incubated with 3-amino-9-ethylcarbazole (Sigma, St.
Louis, MO) solution for 20 minutes to visualize the
peroxidase complex. The sections were mounted with
Aquamount medium under coverslips. Control sections were
incubated with the second antibody only.
Review and Scoring of Stained Sections
The sections stained by IHC or ISH for 15- LOX-2 were
reviewed by routine microscopy and scored as positive or
negative, where positive staining indicates that 10% or more
of the epithelial cells were immunopositive. A statistical
analysis was performed using the McNemar test to
determine the association between the staining results in
distant normal and cancerous tissues. The Kendall test is
used to determine the accordance between ISH and IHC.
P values were generated using Statistica version 4.1 for the
PowerMac (StatSoft, Tulsa, OK).
Cell Cultures and Treatment
The esophageal cancer TE cells were plated in tissue
culture dishes and grown in Dulbecco’s modified Eagle’s
minimal essential medium with 10% fetal bovine serum at
378C in a humidified atmosphere of 95% air and 5%CO2. The
EEC cells were grown in serum-free keratinocyte growth
medium (GIBCO-Invitrogen, Carlsbad, CA) at 378C in a
humidified atmosphere of 95%air and 5%CO2. HET-1A cells
were grown in LHC-8 medium in tissue culture dishes
precoated with a mixture of 18 g of fibronectin, 18 l of
vitrogen, 180 l of 10 bovine serum albumin, and 2 ml of
LHCbasal medium (all fromBiofluids, Rockville, MD) at 378C
in a humidified atmosphere of 96.5% air and 3.5% CO2. To
detect cell viability after treatment with NS398, TE-1, TE-3,
TE-7, TE-8, and TE12 cells were treated with and without
NS398 (50 or 100 M) for 5 days. The culture medium was
replaced once at 72 hours. On day 5, the cells were fixed
with 10% trichloroacetic acid and stained with 0.4%
sulforhodamine B in 1% acetic acid, and then the optical
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densities were read on an automated spectrophotometric
plate reader at a single wavelength of 490 nm. The
percentage of growth inhibition was calculated from the
equation: % Control=(ODt /ODc)100, where ODt and ODc
are the values of optical densities in treated and control
cultures, respectively.
RNA Purification and Analysis by Northern Blotting
RNA were extracted from the monolayer cultures when
they became about 90% confluent using Tri - reagent (Molec-
ular Research Center, Cincinnati, OH). For the Northern blot
analysis, 30 g of total cellular RNAwas fractionated on 1.2%
formaldehyde agarose gels, stained with ethidium bromide,
and transferred in 10 saline–sodium citrate (SSC) to nylon
filters by capillary transfer. The 15-LOX-2–cDNA fragment
was released from pTOPO2.1 using EcoRI and used as the
probe for Northern blotting. The probe was labeled with 32P to
a specific activity of approximately 2109 dpm/g using
random hexanucleotides as primers [22]. The filters were
prehybridized and hybridized at 688C in Rapid-Hyb buffer
(Amersham-Phamarcia Biotechnology, Arlington Heights,
IL) with probes used at 107 cpm/filter. The filters were
washed with 2 SSC and 0.1% sodium dodecyl sulfate
(SDS) for 10 minutes at 238C, and with 0.1 SSC and 0.1%
SDS for 20 minutes at 688C; then they were placed against a
Hyperfilm-MP (Amersham-Pharmacia Biotechnology) for
autoradiography.
Protein Extraction and Western Blotting
Cellular proteins were extracted from esophageal cells in
a lysis buffer containing 30 mM Tris–HCl (pH 7.5), 150 mM
NaCl, 2 mM EDTA, 10 mM sodium pyrophosphate, 2 mM
orthoranadate, 1% Triton X-100, 1% NP40, 100 mM sodium
fluoride, 0.2 mM phenylmethylsulfonyl fluoride, and one
tablet of protease inhibitor cocktail (Roche Molecular
Biochemicals, Indianapolis, IN). The protein concentration
in the samples was measured using the Protein Assay Kit II
(Bio-Rad Laboratories, Hercules, CA). Protein samples
(100 g) extracted from each cell line were subjected to gel
electrophoresis in 10% denaturing polyacrylamide slab gels
in the presence of SDS. The proteins were then transferred
electrophoretically to a hybond-C nitrocellulose membrane
(Amersham-Pharmacia Biotechnology) at 150 V for 2 hours
at 48C. The membrane was subsequently immersed in 0.5%
Ponceau S in 1% acetic acid to stain the proteins and to
validate that equal amounts of protein were loaded in each
lane and transferred efficiently. After incubating the nitro-
cellulose membranes overnight in a blocking solution con-
taining 5% bovine serum albumin in TBST, the membranes
were incubated for 3 hours with rabbit anti–15-LOX-2 anti-
body (1:1000) and subsequently with a second antibody from
the Electrochemiluminescence (ECL) kit from Amersham-
Pharmacia Biotechnology, according to the manufacturer’s
instructions. The membranes were then washed three times
in PBS containing 0.1% Tween-20, incubated with ECL
solution (Amersham-Pharmacia Biotechnology) for 1 to
2 minutes, and exposed to the X-ray film for detection
of chemiluminescence. After that, the membranes were
stripped and reprobedwith anti–b -actin antibody (Sigma) for
verification of equal protein loading.
Inhibition of 5-Bromo-2 0 -Deoxyuridine (BrdU)
Incorporation Through 15-LOX-2 Transfection
The esophageal cancer cell lines TE-1, TE-8, and TE-12
were grown on monolayer culture and then transiently
transfected with either pEGFP–15-LOX-2 expression vec-
tor or pEGFP empty vector as the control (both vectors were
provided by Dr. Dean G. Tang) for 12 hours; 10 M BrdU
was added to the growth medium and the cells were cultured
for an additional 8 hours. The cells were fixed with 4%
paraformaldehyde at room temperature for 10 minutes to
preserve the green fluorescent protein (GFP) and permea-
bilized in 1% Triton X-100 for 20 minutes at room temper-
ature. The cells were then subjected to BrdU immunostaining
as previously described by Tang et al. [23].
Detection of 15-LOX-2 Expression Using Quantitative
Real -Time Reverse Transcriptase (RT) PCR
The numbers of 15-LOX-2 mRNA copies in the untreated
and treated esophageal cancer cells were determined by
real - time quantitative RT-PCR using a Lightcycler fluores-
cence temperature rapid air cycler (Roche Molecular Bio-
chemicals) as previously described by Shappell et al. [19].
The primers used, 50 -GCC-TCT-CGC-CAT-CCA-GCT-30
( forward) and 50 -TGC-CGA-GTT-CTC-CTT-CCA-TGA-
30 ( reverse), resulted in a 126-bp amplified product.
Results
Expression of 15-LOX-2 in Esophageal Cell Lines
As shown in Figure 1, EECs, established from normal
esophagus, expressed 15- LOX-2 at the highest levels.
A.
EE
C 
HE
T-
1A
 
TE
-1
 
TE
-7
TE
-3
 
TE
-8
 
TE
-1
2 
15-LOX-2 
28S  
B.
EE
C 
HE
T-
1A
 
TE
-1
 
TE
-7
TE
-3 
TE
-8 
TE
-1
2 
15-LOX-2 
 β-actin  
15-LOX-2 
NS 
Figure 1. Analysis of 15 -LOX-2 mRNA and protein using Northern (A ) and
Western (B ) blotting. Normal esophageal cells (EECs ), SV40 - immortalized
esophageal epithelial cell line HET-1A, and esophageal cancer cell lines TE-1,
TE -3, TE -7, TE -8, and TE -12 were grown in monolayer cultures to about
90% confluence. The total RNA and protein were isolated and subjected to
Northern and Western blot analyses, respectively. The experiments were
repeated once with similar results.
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In contrast, the esophageal cancer cell lines TE-7 and TE-12
expressed 15-LOX-2 at very low levels. Neither 15-LOX-2
mRNA nor the corresponding protein was detectable in the
SV40- immortalized premalignant EEC line HET-1A or in the
TE-1, TE-3, or TE-8 cell lines. In the Western blots, all cell
lines produced nonspecific bands, except for normal EECs
(Figure 1B ) or other normal epithelial cells (e.g., of the
prostate, breast, skin, and bronchus; data not shown). The
reason the nonspecific bands appeared solely in tumor lines
is unknown; however, it may represent different variants of
15-LOX-2, which have been reported in prostate and lung
cancer cells [23,24].
Differential Expression of 15-LOX-2 in Normal and
Malignant Esophageal Tissues
As shown in Table 1, 27 of 37 normal squamous
epithelium samples from the sectioned margins of esoph-
ageal cancers were positive for 15-LOX-2 mRNA,
according to the ISH experiments, and 28 of 37 samples
were positive for 15-LOX-2 protein, according to immu-
nohistochemical analysis. On the other hand, only 3 of 16
esophageal adenocarcinoma samples and 28 of 47 SCC
samples were positive for 15-LOX-2 protein ( immunohis-
tochemical analysis), and only 3 of 16 esophageal
adenocarcinoma samples and 26 of 47 SCC samples
expressed 15-LOX-2 mRNA (ISH). The positive staining
usually occurred at the differentiated areas of cancer nests
or suprabasal cells of normal mucosa; basal, undifferenti-
ated tumor, and stromal cells were virtually negative
(Figure 2). The McNemar test showed P<.01 for both
Table 1. Differential Expression of 15 - LOX-2 in Esophageal Tissues.
Detection method % (Number of positive / total)
Normal Adenocarcinoma SCC
ISH 73 (27 /37 ) 19 (3 / 16 ) 60 (28 /47 )*
IHC 76 (28 /37 ) 19 (3 / 16 ) 55 (26 /47 )*
*P< .01 by McNemar test for the 33 paired samples of normal squamous
epithelia and SCCs.
Figure 2. Differential expression of 15 -LOX-2 mRNA and protein in normal and malignant esophageal surgical specimens. 15 - LOX-2 mRNA and protein were
detected using ISH and IHC, respectively. Consecutive sections of formalin - fixed and paraffin -embedded human esophageal carcinomas and distant normal
tissues were hybridized with 15 -LOX-2 antisense digoxigenin - labeled cRNA probe, which results in purple to blue staining of the positive signal in the cytoplasm.
IHC was performed by using polyclonal rabbit anti –15 -LOX-2 antibody, and the AEC was the chromogen, resulting in red staining of the positive signal in the
cytoplasm. (A ), (C ), (D ), (E ), ( F )=200 original magnification; (B )=100 magnification.
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the ISH and IHC results between normal and SCC tissues
(Table 1). The Kendall test showed that t=0.88, SE=0.03,
and P<.00001, indicating a strong concordance between
our ISH and IHC results.
Inhibition of Esophageal Cancer Cell Proliferation by
Restoration of 15-LOX-2 Expression
To evaluate the role of 15-LOX-2 in inhibiting
esophageal cancer cell proliferation, we transiently trans-
fected either the GFP reporter expression vector of 15-
LOX-2, pEGFP–15-LOX-2, or the empty pEGFP vector
as the control into esophageal cancer cell lines TE-1,
TE-8, and TE-12 and then treated these cells with BrdU.
After BrdU immunostaining, we counted more than 200
GFP-positive cells for positive or negative BrdU staining
in both the control and the 15-LOX-2–transfected cell
lines. The data (Figure 3) showed that transient trans-
fection of 15-LOX-2 reduced BrdU incorporation by 33%
in TE-1, 26% in TE-8, and only 10% in TE-12 (a c2 test
showed P values of .01, .05, and .34, respectively). One
of the representative figures is shown in Figure 4. These
data demonstrated that 15-LOX-2 inhibited BrdU incor-
poration more in 15-LOX-2–negative esophageal cancer
cells (TE-1 and TE-8) than in 15-LOX-2–positive
esophageal cancer cells (TE-12), suggesting that 15-
LOX-2 reduces cancer cell proliferation.
Modulation of 15-LOX-2 and Reduced Cell Viability after
Treatment with NS398
Our previous studies demonstrated that the NSAID,
NS398, could induce esophageal cancer cells to undergo
apoptosis, which was associated with COX-2 expression
and upregulation of 15-LOX-1 [8,14]. In the present study,
we investigated the modulation of 15-LOX-2 using NS398 in
esophageal cancer cell lines. NS398 at 100 M was able to
induce 15-LOX-2 mRNA expression, as detected by
quantitative real - time RT-PCR (Figure 5). To test whether
the upregulation of 15-LOX-2 was associated with cell
viability, we grew these cells on a monolayer culture and
treated them with NS398 (50 and 100 M) for 5 days. The
cell viability assay showed that the treatment of these cell
lines with NS398, especially at the concentration of 100 M,
was associated with upregulation of 15-LOX-2 (Figure 6).
As shown in our previous study in TE-8 cells, the reduced
cell viability after treatment with 100 MNS398 resulted from
the induction of apoptosis [8,14].
Discussion
Arachidonic acid is converted to prostaglandins, prostacy-
clin, and thromboxane by COX and to hydroxyeicosatetrae-
noic acids (HETEs) or leukotrienes by LOX [25]. Three
LOXs have been discovered in humans: 5-LOX, 12-LOX,
and 15-LOX [18]. 15-LOX-1 and 15-LOX-2, the two
known isoenzymes of 15-LOX, differ from each other in
tissue distribution and enzyme activity. For example, the
tissue distribution of 15-LOX-2 is more limited than that of
15-LOX-1 [17]. 15-LOX-2 converts arachidonic acid exclu-
sively to 15S-hydroperoxyeicosatetraenoic acid (15-HPETE),
which is reduced by cellular peroxidases to 15S -hydrox-
yeicosatetraenoic acid (15-HETE), whereas 15-LOX-1
metabolizes linoleic acid to 13S -hydroxyoctadecadienoic
acid. Unlike 15-LOX-1, 15-LOX-2 metabolizes linoleic acid
less efficiently than it does arachidonic acid [17].
Our previous study demonstrated that 15-LOX-1 is
expressed in normal esophageal tissues and reduced in
esophageal cancer tissues. We also found that certain
NSAIDs can restore 15-LOX-1 expression in esophageal
cancer cells and that the induction of 15-LOX-1 expression
is critical to apoptosis induction by these NSAIDs.
Both NS398, a COX-2–selective inhibitor, and sulindac, a
nonselective COX inhibitor, induced the expression of 15-
LOX-1 in a time-dependent manner [14].
The present study is the first to demonstrate that 15-LOX-
2 mRNA and protein are expressed in normal esophageal
epithelium and cells but downregulated in esophageal cancer
cell lines and tissue specimens. The data also showed that
10 of 37 samples of normal esophageal epithelium did not
express 15-LOX-2, indicating that the morphological normal
epithelium obtained from the sectioned margins of esoph-
ageal carcinomas may not have been truly ‘‘normal’’ at the
molecular level, although the function of 15-LOX-2 in
esophageal epithelium and the cause of its downregulation
in esophageal cancer remain unclear. In prostate tissues, the
uniform expression of 15-LOX-2 in prostate apical or
secretory cells suggests a role for this enzyme in secretion
function. A reduced expression of 15-LOX-2 in atrophic
prostate glands and prostate adenocarcinoma may thus
parallel a reduction of secretory differentiation [18]. The loss
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Figure 3. Inhibition of esophageal cancer cell proliferation by the expression
of 15 - LOX-2. Esophageal cancer cell lines TE -1, TE -8, and TE -12 were
transiently transfected with the control or 15 - LOX-2 expression vectors for
12 hours and treatedwith BrdU for 8 hours. The cells were then stained with anti–
BrdU antibody ( see Materials and Methods ) and more than 200 GFP-positive
cells were counted for positive or negative BrdU staining. The percentage of
inhibition of BrdU incorporation was calculated from the equation:
% Inhibition= [1 (N b /Ng ) ]100, where Nb and Ng are the numbers of
BrdU -positive cells in GPF -positive cells of 15 - LOX-2– transfected and
control cultures, respectively. The data showed that 15 - LOX-2 significantly
reduced BrdU incorporation in 15 -LOX-2–negative esophageal cancer cells.
The experiments were performed in triplicate with similar results.
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of 15-LOX-2 expression may alter the metabolism of
arachidonic acid and linoleic acid and reduce 15-HETE
formation, which may be crucial events in cancer develop-
ment and progression. A recent study demonstrated that 15-
LOX-2 could suppress prostate cancer development by
inhibiting cell cycle progression [23]. Our present data
indicate that the expression of 15-LOX-2 can significantly
reduce BrdU incorporation in 15-LOX-2–negative esoph-
ageal cancer cells and so inhibits cell proliferation.
This study also shows that NS398 can induce 15-LOX-2
expression and that this induced expression is associated
with reduced cell viability. The molecular mechanism of this
event is unclear. The relationships or interactions among
COX-2, 15-LOX-1, and 15-LOX-2 are also unknown.
Taken together, the data from this study of 15-LOX-2 and
our previous studies of COX-2 [7,8 ] and 15-LOX-1 [14]
indicate that COX-2 is overexpressed in esophageal cancer
cells and tissues and that the expression of 15-LOX-1 and
Figure 4. Inhibition of BrdU incorporation by 15 -LOX-2 in esophageal cancer cell lines. 15 -LOX-2 expression vectors were transiently transfected into the
esophageal cancer cell lines TE -1 (A ), TE -8 (B ), and TE -12 (C ), respectively, for 12 hours and then treated with BrdU for 8 hours ( see Materials and Methods ).
After BrdU immunostaining, more than 200 cells were counted for positive staining of GFP (green ), for positive or negative BrdU ( red ) staining in these cells.
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15-LOX-2 is reduced. Moreover, certain NSAIDs can induce
apoptosis in esophageal cancer cells in association with a
reduced COX-2 activity and an upregulation of 15-LOX-1
and 15-LOX-2. Therefore, further studies, including trans-
fection of 15-LOX-1 and 15-LOX-2 expression vectors and
antisense COX-2 constructs into esophageal cancer cell
lines, may enhance our understanding of the importance of
these enzymes in esophageal carcinogenesis.
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Figure 5. Induction of 15 -LOX-2 expression after treatment with NS398
using quantitative RT-PCR. Esophageal cancer cell lines TE -1, TE -3, TE -7,
TE -8, and TE -12 were grown on monolayer and treated with NS398
(100 M) for 5 days. Afterwards, total cellular RNAwas isolated and subjected
to real - time RT-PCR analysis. The experiments were repeated once.
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Figure 6. Cell viability assay. Esophageal cancer cell lines TE -1, TE -3, TE -7,
TE -8, and TE-12 were treated with and without NS398 (50 or 100 M) for
5 days. Culture medium was replaced once at 72 hours. On day 5, the cells
were fixed with 10% trichloroacetic acid and stained with 0.4% sulforhodamine
B in 1% acetic acid, and then the optical densities were read on an automated
spectrophotometric plate reader at a single wavelength of 490 nm.
The percentage of growth inhibition was calculated from the equation:
% Control = (ODt /ODc )100, where ODt and ODc are the values of optical
densities in treated and control cultures, respectively. The experiments were
repeated once.
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